<?xml version="1.0" encoding="UTF-8"?><ValueSet xmlns="http://hl7.org/fhir"><id value="detectedissue-category"/><meta><lastUpdated value="2015-10-24T07:41:03.495+11:00"/><profile value="http://hl7.org/fhir/StructureDefinition/valueset-shareable-definition"/></meta><extension url="http://hl7.org/fhir/StructureDefinition/valueset-oid"><valueUri value="urn:oid:2.16.840.1.113883.4.642.2.103"/></extension><url value="http://hl7.org/fhir/ValueSet/detectedissue-category"/><version value="1.0.2"/><name value="Detected Issue Category"/><status value="draft"/><experimental value="true"/><publisher value="FHIR Project team"/><contact><telecom><system value="other"/><value value="http://hl7.org/fhir"/></telecom></contact><date value="2015-10-24T07:41:03+11:00"/><description value="Kinds of issues or contraindications, such as &#39;drug-drug interaction&#39;, &#39;duplicate therapy&#39;, etc."/><compose><include><system value="http://hl7.org/fhir/v3/ActCode"/><filter><property value="concept"/><op value="is-a"/><value value="_AdministrationDetectedIssueCode"/></filter></include><include><system value="http://hl7.org/fhir/v3/ActCode"/><filter><property value="concept"/><op value="is-a"/><value value="_SupplyDetectedIssueCode"/></filter></include></compose></ValueSet>